News from the world KOLINPHARMA S.p.A

KOLINPHARMA

E-commerce

I prodotti Kolinpharma

News
News from the world KOLINPHARMA

Prointex

24/02/2026 - published at 17.59

KOLINPHARMA^® launched PROINTEX^® , the innovative nutraceutical that marks the start of its new gastroenterology line

PROINTEX® expands the range of products offered by Kolinpharma®, introducing the company...

Kolinpharma featured in Il Sole 24 Ore’s “Growth Leaders 2026” ranking

12/11/2025 - published at 14.57

Kolinpharma features in Il Sole 24 Ore’s “Growth Leaders 2026” ranking

Kolinpharma confirms its strong growth in the prestigious "Growth Leaders 2026" ranking by Il Sole 24 Ore.

EUROPE’S LONG-TERM GROWTH CHAMPIONS

31/10/2025 - published at 12.51

Kolinpharma^® ranks first among European companies in the Health Care & Life Sciences sector in the ranking drawn up by the Financial Times and Statista

We are pleased to share the results of the second edition of the Financial Times and Statista "Europe's Long-term Growth Champions" ranking, which celebrates resilience and innovation in Europe...

Enterprise and Value award

26/09/2025 - published at 15.28

KOLINPHARMA awarded the "Enterprise and Value" award

This recognition reaffirms our mission: to create value by making a positive impact on people, communities and the environment in which we operate.

17/07/2025 - published at 12.55

From confusion to clarity: why Italy must establish specific guidelines for nutraceuticals. Kolinpharma^®'s proposal.

Although nutraceuticals has been a recognized and studied discipline for nearly forty years, a significant regulatory gap persists...

22/03/2025 - published at 12.56

Kolinpharma^® receives new award, the “America Innovation” award, from Fondazione Italia Usa

The ITA-USA Foundation establishes the America Innovation Award, an initiative that celebrates the innovators and innovative protagonists of the best Italian startups...

CREDIT AWARDS

20/03/2025 - published at 12.56

Kolinpharma^® recognizes the Credit Awards also this year: a further example of corporate excellence in financial management

Over 130 Italian companies have been awarded at the Credit Reputation Awards 2025...

23/12/2024 - published at 12.58

KOLINPHARMA^® has obtained the recognition of "Growth Leader 2025" for the sixth consecutive year

Kolinpharma^® has been confirmed once more “Growth Leader”, among the 500 Italian companies...

20/12/2024 - published at 15.16

KOLINPHARMA® INCLUDED AMONG THE 100 ITALIAN EXCELLENCES

A prestigious recognition for the company

CPHI 2024

10/10/2024 - published at 12.59

Kolinpharma^® present in great style at CPHI 2024 in Milan, the most important fair in the world in the pharmaceutical sector

On this occasion, Kolinpharma^® presented many new products, such as the new Neurological Line that joins...

22/05/2024 - published at 13.00

KOLINPHARMA^®: new patent in China for Doltendix®

KOLINPHARMA^® achieved the first patent in China for Doltendix®

29/03/2024 - published at 13.00

KOLINPHARMA^®: has received the prize Credit Reputation Award

kipfer

09/01/2024 - published at 13.02

Kolinpharma^® is pleased to announce the launch of KIPFeR®

KIPFeR^® is the nanoparticle iron supplement that Kolinpharma^® has launched on the market following a new agreement with Nemysis LTD.

Declinex

01/09/2023 - published at 13.03

KOLINPHARMA^® has presented Declinex^®, initiating the new line of products dedicated for the neurodegenerative diseases

Thanks to the active components such as dry extract of green tea

06/03/2023 - published at 15.15

Kolinpharma^® for gender equity a PMIHeroes

Rita Paola Petrelli was being a guest on the podcast PMIHeroes in Ifis Bank

06/12/2022 - published at 15.23

KOLINPHARMA^®: has achieved the first patent for Xinprox^®

Now, Kolinpharma has 46 patents in total

23/11/2022 - published at 15.34

KOLINPHARMA^®: has achieved the award as “Leader of growth 2023” for the fifth consecutive year

Even this year the company is one between 500 Italian enterprises that they were distinguished for the major growth of turnover

25/10/2022 - published at 16.47

KOLINPHARMA^® signs an agreement with ASTAREAL^® AB for distribution in the Asian market

An important three-year agreement for distribution of products in Mainland China, Hong Kong, Macao and Taiwan

19/11/2021 - published at 17.03

KOLINPHARMA^® “Growth Leader 2022” for the fourth consecutive year

The company is confirmed as one of the 450 Italian companies that recorded the highest turnover growth rates

05/08/2021 - published at 16.06

Kolinpharma^® at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan

KOLINPHARMA^® strengthens its marketing and brand awareness strategy

26/08/2020 - published at 14.14

KOLINPHARMA^® expands its product portfolio with IVUXUR^® TABLETS.

KOLINPHARMA^® presents the new product IVUXUR^® TABLETS, which is added to the other 9 patented or patent pending products

21/05/2020 - published at 12.38

KOLINPHARMA^® scales the ranking of nutraceuticals, positioning itself at 76th place. + 4% medical requirements in 1Q 2020 vs 1Q 2019

16/04/2020 - published at 14.49

KOLINPHARMA^®:first patent for XINEPA^® in Israel and fifth outside Italy

Xinepa^® is a nutraceutical product already in possession of a double patent in Italy

31/03/2020 - published at 11.48

KOLINPHARMA^® donates a pulmonary ventilator for the hospitals of city of catanzaro to fight COVID 19

KOLINPHARMA^® supports physicians and health professionals by becoming a partner in the fundraising initiative "Politeama Foundation

10/03/2020 - published at 16.45

KOLINPHARMA^® obtains the patent in the U.S. of Dolatrox^®

It is the fourth patent that is added to Ivuxur^® and to the 2 of Xinepa^®

30/10/2019 - published at 12.21

KOLINPHARMA^® is the first nutraceutical company to obtain UNI ISO 37001 certification

An international standard for management systems to prevent corruption.

17/10/2019 - published at 12.29

KOLINPHARMA^® at the Varese Convention on Stock Markets and Corporate Capital

Kolinpharma participated in the Conference "From bond issues to listing: the collection of capital for growth and business development"

24/05/2019 - published at 10.54

KOLINPHARMA^® invests in product quality and safety

Strict product controls guarantee quality and safety for the consumer.

01/03/2019 - published at 17.42

KOLINPHARMA^® at the Convention about reproduction disorders in Modena

KOLINPHARMA participated as sponsor during the Regional Convention in Emilia Romagna – Right use of food supplement in the most common reproduction disorders

14/02/2019 - published at 12.45

KOLINPHARMA^® is getting closer to consumers with new products’ web-sites.

The new web-sites are online, dedicated to KOLINPHARMA’s products

23/01/2019 - published at 12.12

KOLINPHARMA^® and the “La Sapienza” University of Rome train future managers.

KOLINPHARMA achieved an agreement with “La Sapienza” University about the organization of a II level Master Degree

21/11/2018 - published at 17.15

Effective and innovative ASI for osteoarthritis

The SIOT2018 is a reference point for orthopedics

28/06/2018 - published at 17.07

MILESAX Finalist Project

The excellence in scientific information and the central position of the patient.

28/05/2018 - published at 09.13

AIM Italia Conference 2018, Milan

May 28th: event with institutional investors

25/05/2018 - published at 09.19

Growth of medical prescriptions 2018

Reinforcement of sales network. Nominated the International Manager.

13/04/2018 - published at 09.23

QUOTATION- BONUS: Decree implementing about tax credit

It will be held on April 18th 2018, Milan

10/04/2018 - published at 09.40

Walk with the SME to the quotation on AIM-Borsa Italiana

The event was organized and invented by IR Top Consulting, partner Equity Markets of Borsa Italiana

05/02/2018 - published at 09.45

Renovate the certifications by Bureau Veritas

KOLINPHARMA has to renovate its own company and product

05/02/2018 - published at 09.48

The scientific medical information: an extraordinary job, because it is ethical, scientific and it empathizes with the doctor

KOLINPHARMA always took care about the selection of its collaborators.

05/02/2018 - published at 09.53

Functional Growth: the policy of “internal growth”

KOLINPHARMA wants to give functional growth opportunities to its own collaborators

05/02/2018 - published at 09.58

Marketing: a specific science which studies the market

Kolinpharma completed the company organization, including a Junior Product Manager

02/02/2018 - published at 10.05

The attention to the pharmaceutical forms for an easier patient’s compliance.

The company complements to the traditional pharmaceutical forms, new solutions, easy in their use.

09/01/2018 - published at 12.16

KOLINPHARMA^® in the European research

Since 2017, the company faced an international research.

08/01/2018 - published at 10.13

A QR code which shows itself to who is blind

An international patent highlights the QR-code position to a blind person, thanks to the braille code.

08/01/2018 - published at 10.16

Tamper evident: ever-changing patented technology

The company adopted a packaging closure, which is usable even for blind people.

02/01/2018 - published at 12.15

KOLINPHARMA^® chooses Hoffmann & Eitle Italia as partner

One of the biggest European law firm specialized in patents, models and design and of all internation industrial protection rights.

02/01/2018 - published at 10.24

A quoted company at AIM, as depositary and logistic: Bomi Group

KOLINPHARMA gave to BOMI Group the storage and the transport of its products to distributors.

02/01/2018 - published at 10.28

Research and Development team (R&D): effectiveness and innovation

The company’s beating heart, the R&D team, is part of the company.

29/12/2017 - published at 10.33

The 231, a model which commit us everyday

All the direct and indirect staff, firm the Company Ethical Code, with consciousness and commitment about what it is necessary follow.

21/12/2017 - published at 10.38

Raw material: a constant research for excellence

The Curcuma is a raw material which everybody talk about, for its scientifically proved qualities.

22/12/2016 - published at 14.16

2016: KOLINPHARMA^® revenue redoubles!

The effort of all, from company heart to sales network, has enabled us to reach the target set at the begin of the year: the revenue doubling, touched 2,5 million in 2016.

22/12/2016 - published at 17.37

All our validations are confirmed.

For 2016, KOLINPHARMA is considered in compliance to ISO 9001 and ISO 22000 requirements. Confirmed also Kosher, Halal, Milk Free, Doping Free, Gluten Free and Casa Savoia requirements. Read all.

22/12/2016 - published at 16.56

Doping Free Validation: quality and ethic

Even this year, after many controls, it was confirmed the total absence of doping substances and thanks to it, we received the Doping free validation. It guarantees the use of our products by amateur or agonistic athletes.

Media

Almetax Easy and tablets

Certified products

Company validations

Consumer Protection

Corporate compliance

Profile and organization

Research and development

Respect the environment

Xinepa Easy and tablets

Company profile

Contact media relations

“Science accuracy and listen to people”

“Science accuracy and listen to people”